Skip to main content
Erschienen in: Breast Cancer Research and Treatment 3/2009

01.12.2009 | Preclinical Study

Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR

verfasst von: Anieta M. Sieuwerts, Jaco Kraan, Joan Bolt-de Vries, Petra van der Spoel, Bianca Mostert, John W. M. Martens, Jan-Willem Gratama, Stefan Sleijfer, John A. Foekens

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Detection of circulating tumor cells (CTCs) in whole blood from metastatic cancer patients by the CellSearch™ CTC Test (Veridex LLC, Warren, NJ, USA) has been shown to have clinical relevance. In addition to enumeration, there is great interest in molecular characterization of these CTCs. We aimed to establish a robust method to perform mRNA expression analysis of multiple genes by a real-time reverse transcriptase (RT)-PCR on small numbers of CTCs enriched from whole blood by the CellSearch™ system. Despite the 4 log depletion of leukocytes after CellSearch enrichment, the CTC-enriched fractions still contained leukocytes, in particular B-lymphocytes, which severely interfered with our CTC-specific gene expression profiling. After extensive washing and leukocyte-specific depletion by anti-CD45 coated magnetic beads prior to CellSearch™ enrichment, the number of leukocytes present in the enriched fraction was still high (range 60–929). However, by using a set of genes with no or minor expression by leukocytes, we succeeded to perform quantitative gene expression profiling specific for as little as one breast cancer CTC present in a CTC-enriched environment typically containing over 800 contaminating leukocytes. Our method allows molecular characterization specific for as little as one CTC, and can be used to expand the understanding of the biology of metastasis and, potentially, to improve patient management.
Literatur
5.
Zurück zum Zitat Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW et al (2006) Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403–6640. doi:10.1158/1078-0432.CCR-05-1769 CrossRefPubMed Budd GT, Cristofanilli M, Ellis MJ, Stopeck A, Borden E, Miller MC, Matera J, Repollet M, Doyle GV, Terstappen LW et al (2006) Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer. Clin Cancer Res 12:6403–6640. doi:10.​1158/​1078-0432.​CCR-05-1769 CrossRefPubMed
6.
Zurück zum Zitat Morgan TM, Lange PH, Vessella RL (2007) Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 12:3000–3009. doi:10.2741/2290 CrossRefPubMed Morgan TM, Lange PH, Vessella RL (2007) Detection and characterization of circulating and disseminated prostate cancer cells. Front Biosci 12:3000–3009. doi:10.​2741/​2290 CrossRefPubMed
7.
Zurück zum Zitat Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE (2007) Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 53:1206–1215. doi:10.1373/clinchem.2006.081828 CrossRefPubMed Xi L, Nicastri DG, El-Hefnawy T, Hughes SJ, Luketich JD, Godfrey TE (2007) Optimal markers for real-time quantitative reverse transcription PCR detection of circulating tumor cells from melanoma, breast, colon, esophageal, head and neck, and lung cancers. Clin Chem 53:1206–1215. doi:10.​1373/​clinchem.​2006.​081828 CrossRefPubMed
8.
Zurück zum Zitat Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA (2007) Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 43:2645–2650PubMed Sleijfer S, Gratama JW, Sieuwerts AM, Kraan J, Martens JW, Foekens JA (2007) Circulating tumour cell detection on its way to routine diagnostic implementation? Eur J Cancer 43:2645–2650PubMed
10.
Zurück zum Zitat Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340. doi:10.1038/nrc2375 CrossRefPubMed Pantel K, Brakenhoff RH, Brandt B (2008) Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer 8:329–340. doi:10.​1038/​nrc2375 CrossRefPubMed
11.
Zurück zum Zitat Steen S, Nemunaitis J, Fisher T, Kuhn J (2008) Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proceedings (Bayl Univ Med Cent) 21:127–132 Steen S, Nemunaitis J, Fisher T, Kuhn J (2008) Circulating tumor cells in melanoma: a review of the literature and description of a novel technique. Proceedings (Bayl Univ Med Cent) 21:127–132
12.
13.
Zurück zum Zitat Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179:2187–2191. doi:10.1016/j.juro.2008.01.102 CrossRefPubMed Davis JW, Nakanishi H, Kumar VS, Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T, Babaian RJ (2008) Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer. J Urol 179:2187–2191. doi:10.​1016/​j.​juro.​2008.​01.​102 CrossRefPubMed
14.
Zurück zum Zitat Kahan LS (2004) Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. Fed Regist 69:26036–26038 Kahan LS (2004) Medical devices; immunology and microbiology devices; classification of the immunomagnetic circulating cancer cell selection and enumeration system. Final rule. Fed Regist 69:26036–26038
15.
Zurück zum Zitat Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M et al (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058. doi:10.1158/1078-0432.CCR-07-1506 CrossRefPubMed Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M et al (2007) Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 13:7053–7058. doi:10.​1158/​1078-0432.​CCR-07-1506 CrossRefPubMed
16.
Zurück zum Zitat Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP et al (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6:125–132. doi:10.3816/CCC.2006.n.029 CrossRefPubMed Cohen SJ, Alpaugh RK, Gross S, O’Hara SM, Smirnov DA, Terstappen LW, Allard WJ, Bilbee M, Cheng JD, Hoffman JP et al (2006) Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 6:125–132. doi:10.​3816/​CCC.​2006.​n.​029 CrossRefPubMed
17.
Zurück zum Zitat Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791. doi:10.1056/NEJMoa040766 CrossRefPubMed Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW et al (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351:781–791. doi:10.​1056/​NEJMoa040766 CrossRefPubMed
19.
Zurück zum Zitat Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA (2005) How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11:7311–7321. doi:10.1158/1078-0432.CCR-05-0560 CrossRefPubMed Sieuwerts AM, Meijer-van Gelder ME, Timmermans M, Trapman AM, Garcia RR, Arnold M, Goedheer AJ, Portengen H, Klijn JG, Foekens JA (2005) How ADAM-9 and ADAM-11 differentially from estrogen receptor predict response to tamoxifen treatment in patients with recurrent breast cancer: a retrospective study. Clin Cancer Res 11:7311–7321. doi:10.​1158/​1078-0432.​CCR-05-0560 CrossRefPubMed
20.
Zurück zum Zitat Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Methodol 57:289–300 Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc Ser B Methodol 57:289–300
21.
Metadaten
Titel
Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR
verfasst von
Anieta M. Sieuwerts
Jaco Kraan
Joan Bolt-de Vries
Petra van der Spoel
Bianca Mostert
John W. M. Martens
Jan-Willem Gratama
Stefan Sleijfer
John A. Foekens
Publikationsdatum
01.12.2009
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 3/2009
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-008-0290-0

Weitere Artikel der Ausgabe 3/2009

Breast Cancer Research and Treatment 3/2009 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.